Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05070403 · ClinicalTrials.gov registry record · Phase 2
Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
A Phase 2 study of Squamous Cell Carcinoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT05070403: Recruiting Phase 2 study of Squamous Cell Carcinoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT05070403 is a Phase 2 study of Squamous Cell Carcinoma that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 25 participants, below the 104-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05070403, a Phase 2 study of Squamous Cell Carcinoma, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study is to find out if Afatinib can help treat participants with advanced cSCC.
Primary Outcome
Overall response rate (ORR) as defined by proportion of patients who have achieved a complete or partial response per RECIST 1.1 criteria
Conditions Studied
Interventions
- DRUG Afatinib 40 MG
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2028-03 |
| Phase | Phase 2 |
What NCT05070403 shows while recruiting
NCT05070403 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 104-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Afatinib 40 MG is the first listed.
NCT05070403 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05070403 about?
NCT05070403 is a clinical study titled "Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma". The primary purpose of this study is to find out if Afatinib can help treat participants with advanced cSCC.
What is the current status of trial NCT05070403?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2021-10-01. Estimated completion is 2028-03.
What conditions does trial NCT05070403 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma.
What interventions are being tested in trial NCT05070403?
The interventions under investigation include: Afatinib 40 MG (DRUG).
Who is sponsoring clinical trial NCT05070403?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05070403 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05070403's enrollment target sits among peer trials
25 37th of 47 higher than 10 of 47 other Squamous Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Squamous Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin
RECRUITING · Phase 2
-
Toripalimab With Chemotherapy for Sinus Cancer
RECRUITING · Phase 2
-
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
RECRUITING · Phase 2
-
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
RECRUITING · Phase 2
-
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
RECRUITING · Phase 2
-
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI